Methylprednisolone Addition in IVF Treatment of Infertile Couples
Phase 4
- Conditions
- In Vitro Fertilization
- Interventions
- Other: In vitro fertilization treatment for infertility
- Registration Number
- NCT01220791
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Brief Summary
Hypothesis to be tested is whether follicular addition of Methylprednisolone can efficiently control late follicular progesterone rise during IVF treatment
- Detailed Description
The aim is to investigate any potential advantages of adding cortisone supplementation from the follicular phase onwards with regard to premature luteinization, oocyte quality, embryo quality and pregnancy outcome.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 130
Inclusion Criteria
- less than 36, more than 10 antral follicles, FSH<12
Exclusion Criteria
- endometriosis stage III&IV,
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Follicular Medrol In vitro fertilization treatment for infertility In an Antagonist protocol for IVF patients will also receive 4mg tabl. Methylprednisolone twice a day from the day 2 of ovarian stimulation and until the day of the pregnancy test on luteal day-14 post oocyte retrieval No medrol group In vitro fertilization treatment for infertility Patients will receive only Antagonist protocol for IVF as usual
- Primary Outcome Measures
Name Time Method Progesterone rise above 1.5ng.ml on the day of HCG up to 14 days of follicular ovarian stimulation Incidence or high progesterone on the day of HCG triggering
- Secondary Outcome Measures
Name Time Method Clinical pregnancy rate Follow pregnancy until delivery Success rate in IVF cycles
Trial Locations
- Locations (1)
Biogenesis
🇬🇷Thessaloniki, Pylaia, Greece